Critical Insights From ACADIA Pharmaceuticals Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
ACADIA Pharmaceuticals (NASDAQ:ACAD) has been analyzed by 7 analysts, showing a range of ratings from bullish to bearish. The average 12-month price target is $25.0, down from $29.43. Analysts have recently lowered their price targets, reflecting changing market conditions. Despite this, ACADIA shows strong financial performance with a 46.44% revenue growth rate, a net margin of 13.8%, and a low debt-to-equity ratio of 0.11.
October 10, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ACADIA Pharmaceuticals has received mixed analyst ratings, with a lowered average price target of $25.0. Despite this, the company shows strong financial performance with a 46.44% revenue growth rate and a net margin of 13.8%.
The mixed analyst ratings and lowered price targets suggest a neutral short-term impact on ACAD's stock price. However, the company's strong financial performance, including significant revenue growth and profitability, may offset some of the negative sentiment from analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100